Shiga toxins

Toxicon

Volumn 60, Issue 6, 2012, Pages 1085-1107

  Bergan, Jonas ^a,b,c   Dyve Lingelem, Anne Berit ^a,b,c   Simm, Roger ^a,b   Skotland, Tore ^a,b   Sandvig, Kirsten ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Globotriaosylceramide; Ribosome inactivating proteins; Shiga toxin; Verotoxin

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DACARBAZINE; IRINOTECAN SHIGA B CONJUGATE; PROTEIN GB3; RECEPTOR PROTEIN; SHIGA TOXIN; SLT 1A ISOLEUCYLTYROSYLSERYLASPARAGINYLLYSYLLEUCYLMETHIONINE FUSION PROTEIN; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2;

APOPTOSIS; BACTERIAL GENETICS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BINDING AFFINITY; BINDING SITE; CANCER RESISTANCE; COMPLEX FORMATION; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVITY; HUMAN; INTRACELLULAR TRANSPORT; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR IMAGING; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS; TOXIN ANALYSIS; TOXIN SYNTHESIS; TRANSPORT KINETICS;

APOPTOSIS; BIOLOGICAL TRANSPORT; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ESCHERICHIA COLI; SHIGA TOXINS; SHIGELLA DYSENTERIAE; SIGNAL TRANSDUCTION; VIRULENCE FACTORS;

ESCHERICHIA COLI; SHIGELLA DYSENTERIAE;

EID: 84865421575     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.07.016     Document Type: Review

References (328)

1. Allison H.E. Stx-phages: drivers and mediators of the evolution of STEC and STEC-like pathogens. Future Microbiol. 2007, 2:165-174.
2. Allison H.E., Sergeant M.J., James C.E., Saunders J.R., Smith D.L., Sharp R.J., Marks T.S., McCarthy A.J. Immunity profiles of wild-type and recombinant Shiga-like toxin-encoding bacteriophages and characterization of novel double lysogens. Infect. Immun. 2003, 71:3409-3418.
3. Amessou M., Carrez D., Patin D., Sarr M., Grierson D.S., Croisy A., Tedesco A.C., Maillard P., Johannes L. Retrograde delivery of photosensitizer (TPPp-O-beta-GluOH)3 selectively potentiates its photodynamic activity. Bioconjug. Chem. 2008, 19:532-538.
4. Arab S., Lingwood C.A. Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes. Glycoconjug. J. 1996, 13:159-166.
5. Arab S., Lingwood C.A. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J. Cell. Physiol. 1998, 177:646-660.
6. Arab S., Russel E., Chapman W.B., Rosen B., Lingwood C.A. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol. Res. 1997, 9:553-563.
7. Arab S., Rutka J., Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res. 1999, 11:33-39.
8. Arfilli V., Carnicelli D., Rocchi L., Ricci F., Pagliaro P., Tazzari P.L., Brigotti M. Shiga toxin 1 and ricin A chain bind to human polymorphonuclear leucocytes through a common receptor. Biochem. J. 2010, 432:173-180.
9. Armstrong G.D., Fodor E., Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 1991, 164:1160-1167.
10. Austin P.R., Jablonski P.E., Bohach G.A., Dunker A.K., Hovde C.J. Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity. Infect. Immun. 1994, 62:1768-1775.
11. Bast D.J., Sandhu J., Hozumi N., Barber B., Brunton J. Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30. Infect. Immun. 1997, 65:2978-2982.
12. Bast D.J., Banerjee L., Clark C., Read R.J., Brunton J.L. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit. Mol. Microbiol. 1999, 32:953-960.
13. Binnington B., Lingwood D., Nutikka A., Lingwood C.A. Effect of globotriaosyl ceramide fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem. Res. 2002, 27:807-813.
14. Bitzan M., Ludwig K., Klemt M., König H., Büren J., Müller-Wiefel D.E. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol. Infect. 1993, 110:183-196.
15. Bitzan M., Poole R., Mehran M., Sicard E., Brockus C., Thuning-Roberson C., Rivière M. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob. Agents Chemother. 2009, 53:3081-3087.
16. Boerlin P., McEwen S.A., Boerlin-Petzold F., Wilson J.B., Johnson R.P., Gyles C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 1999, 37:497-503.
17. Boivin A., Mesrobeanu L. Sur l'identité entre la toxine thermolabile et neurotrope des corps bacterienne du bacille de Shiga et l'exotoxine présente dans les filtrats des cultures sur bouillon de la même bacterie. C. R. Soc. Biol. 1937, 126:323-325.
18. Boulanger J., Huesca M., Arab S., Lingwood C.A. Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands. Anal. Biochem. 1994, 217:1-6.
19. Boyd B., Tyrrell G., Maloney M., Gyles C., Brunton J., Lingwood C. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs. J. Exp. Med. 1993, 177:1745-1753.
20. Boyd B., Magnusson G., Zhiuyan Z., Lingwood C.A. Lipid modulation of glycolipid receptor function. Availability of Gal(alpha 1-4)Gal disaccharide for verotoxin binding in natural and synthetic glycolipids. Eur. J. Biochem. 1994, 223:873-878.
21. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 1994, 13:223-233.
22. Bridgwater F.A., Morgan R.S., Rowson K.E., Wright G.P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br. J. Exp. Pathol. 1955, 36:447-453.
23. Brigotti M., Carnicelli D., Alvergna P., Mazzaracchio R., Sperti S., Montanaro L. The RNA-N-glycosidase activity of Shiga-like toxin I: kinetic parameters of the native and activated toxin. Toxicon 1997, 35:1431-1437.
24. Brigotti M., Carnicelli D., Arfilli V., Rocchi L., Ricci F., Pagliaro P., Tazzari P.L., Vara A.G., Amelia M., Manoli F., Monti S. Change in conformation with reduction of alpha-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1. J. Biol. Chem. 2011, 286:34514-34521.
25. Brigotti M., Tazzari P.L., Ravanelli E., Carnicelli D., Rocchi L., Arfilli V., Scavia G., Minelli F., Ricci F., Pagliaro P., Ferretti A.V.S., Pecoraro C., Paglialonga F., Edefonti A., Procaccino M.A., Tozzi A.E., Caprioli A. Clinical relevance of Shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr. Infect. Dis. J. 2011, 30:486-490.
26. Brown J.E., Rothman S.W., Doctor B.P. Inhibition of protein synthesis in intact HeLa cells by Shigella dysenteriae 1 toxin. Infect. Immun. 1980, 29:98-107.
27. Bujny M.V., Popoff V., Johannes L., Cullen P.J. The retromer component sorting nexin-1 is required for efficient retrograde transport of Shiga toxin from early endosome to the trans Golgi network. J. Cell. Sci. 2007, 120:2010-2021.
28. Burgess B.J., Roberts L.M. Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the Escherichia coli Shiga-like toxin I A subunit is not essential for cytotoxicity. Mol. Microbiol. 1993, 10:171-179.
29. Bürk C., Dietrich R., Açar G., Moravek M., Bülte M., Märtlbauer E. Identification and characterization of a new variant of Shiga toxin 1 in Escherichia coli ONT: H19 of bovine origin. J. Clin. Microbiol. 2003, 41:2106-2112.
30. Calderwood S.B., Auclair F., Donohue-Rolfe A., Keusch G.T., Mekalanos J.J. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc. Natl. Acad. Sci. U S A 1987, 84:4364-4368.
31. Calderwood S.B., Acheson D.W., Goldberg M.B., Boyko S.A., Donohue-Rolfe A. A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit. Infect. Immun. 1990, 58:2977-2982.
32. Cameron P., Smith S.J., Giembycz M.A., Rotondo D., Plevin R. Verotoxin activates mitogen-activated protein kinase in human peripheral blood monocytes: role in apoptosis and proinflammatory cytokine release. Br. J. Pharmacol. 2003, 140:1320-1330.
33. Cao C., Kurazono H., Yamasaki S., Kashiwagi K., Igarashi K., Takeda Y. Construction of mutant genes for a non-toxic verotoxin 2 variant (VT2vp1) of Escherichia coli and characterization of purified mutant toxins. Microbiol. Immunol. 1994, 38:441-447.
34. Chark D., Nutikka A., Trusevych N., Kuzmina J., Lingwood C. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. Eur. J. Biochem. 2004, 271:405-417.
35. Chen J.-L., Ahluwalia J.P., Stamnes M. Selective effects of calcium chelators on anterograde and retrograde protein transport in the cell. J. Biol. Chem. 2002, 277:35682-35687.
36. Cherla R.P., Lee S.-Y., Mees P.L., Tesh V.L. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol. 2006, 79:397-407.
37. Cheung M.C., Revers L., Perampalam S., Wei X., Kiarash R., Green D.E., Abdul-Wahid A., Gariépy J. An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo. Mol. Cancer 2010, 9:28.
38. Chin L.S., Raynor M.C., Wei X., Chen H.Q., Li L. Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor. J. Biol. Chem. 2001, 276:7069-7078.
39. Chiron M.F., Fryling C.M., FitzGerald D.J. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J. Biol. Chem. 1994, 269:18167-18176.
40. Choi N.-W., Estes M.K., Langridge W.H.R. Oral immunization with a Shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis. Vaccine 2005, 23:5168-5176.
41. Clark C., Bast D., Sharp A.M., St Hilaire P.M., Agha R., Stein P.E., Toone E.J., Read R.J., Brunton J.L. Phenylalanine 30 plays an important role in receptor binding of verotoxin-1. Mol. Microbiol. 1996, 19:891-899.
42. Conradi H. Ueber lösliche, durch aseptische Autolyse erhaltene Giftstoffe von Ruhr- und Typhus-Bazillen. Dtsch. Med. Wochenschr 1903, 29:26-28.
43. Conrady D.G., Flagler M.J., Friedmann D.R., Vander Wielen B.D., Kovall R.A., Weiss A.A., Herr A.B. Molecular basis of differential B-pentamer stability of Shiga toxins 1 and 2. PLoS ONE 2010, 5:e15153.
44. Cornick N.A., Helgerson A.F., Mai V., Ritchie J.M., Acheson D.W.K. In vivo transduction of an Stx-encoding phage in ruminants. Appl. Environ. Microbiol. 2006, 72:5086-5088.
45. Couture O., Dransart E., Dehay S., Nemati F., Decaudin D., Johannes L., Tanter M. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit. Mol. Imaging 2011, 10:135-143.
46. Cullen P.J., Korswagen H.C. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat. Cell. Biol. 2012, 14:29-37.
47. De Grandis S., Ginsberg J., Toone M., Climie S., Friesen J., Brunton J. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J. Bacteriol. 1987, 169:4313-4319.
48. De Rosa M.F., Ackerley C., Wang B., Ito S., Clarke D.M., Lingwood C. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J. Biol. Chem. 2008, 283:4501-4511.
49. Decaudin D. Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs 2004, 15:737-745.
50. DeGrandis S., Law H., Brunton J., Gyles C., Lingwood C.A. Globotetraosylceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 1989, 264:12520-12525.
51. Del Nery E., Miserey-Lenkei S., Falguières T., Nizak C., Johannes L., Perez F., Goud B. Rab6A and Rab6A' GTPases play non-overlapping roles in membrane trafficking. Traffic 2006, 7:394-407.
52. Derby M.C., Lieu Z.Z., Brown D., Stow J.L., Goud B., Gleeson P.A. The trans-Golgi network Golgin, GCC185, is required for endosome-to-Golgi transport and maintenance of Golgi structure. Traffic 2007, 8:758-773.
53. Deresiewicz R.L., Calderwood S.B., Robertus J.D., Collier R.J. Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry 1992, 31:3272-3280.
54. Deresiewicz R.L., Austin P.R., Hovde C.J. The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. Mol. Gen. Genet. 1993, 241:467-473.
55. Di R., Kyu E., Shete V., Saidasan H., Kahn P.C., Tumer N.E. Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae. Toxicon 2011, 57:525-539.
56. Donohue-Rolfe A., Keusch G.T., Edson C., Thorley-Lawson D., Jacewicz M. Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J. Exp. Med. 1984, 160:1767-1781.
57. Donohue-Rolfe A., Acheson D.W., Kane A.V., Keusch G.T. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect. Immun. 1989, 57:3888-3893.
58. Donta S.T., Tomicic T.K., Donohue-Rolfe A. Inhibition of Shiga-like toxins by brefeldin A. J. Infect. Dis. 1995, 171:721-724.
59. Dowling T.C., Chavaillaz P.A., Young D.G., Melton-Celsa A., O'Brien A., Thuning-Roberson C., Edelman R., Tacket C.O. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother. 2005, 49:1808-1812.
60. Dubos R.J., Geiger J.W. Preparation and properties of Shiga toxin and toxoid. J. Exp. Med. 1946, 84:143-156.
61. Durán J.M., Valderrama F., Castel S., Magdalena J., Tomás M., Hosoya H., Renau-Piqueras J., Malhotra V., Egea G. Myosin motors and not actin comets are mediators of the actin-based Golgi-to-endoplasmic reticulum protein transport. Mol. Biol. Cell. 2003, 14:445-459.
62. Dyve A.B., Bergan J., Utskarpen A., Sandvig K. Sorting nexin 8 regulates endosome-to-Golgi transport. Biochem. Biophys. Res. Commun. 2009, 390:109-114.
63. Dyve Lingelem A.B., Bergan J., Sandvig K. Inhibitors of intravesicular acidification protect against Shiga toxin in a pH-independent manner. Traffic 2012, 13:443-454.
64. Eisenhauer P.B., Chaturvedi P., Fine R.E., Ritchie A.J., Pober J.S., Cleary T.G., Newburg D.S. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect. Immun. 2001, 69:1889-1894.
65. El Alaoui A., Schmidt F., Amessou M., Sarr M., Decaudin D., Florent J.-C., Johannes L. Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug. Angew. Chem. Int. Ed. Engl. 2007, 46:6469-6472.
66. El Alaoui A., Schmidt F., Sarr M., Decaudin D., Florent J.-C., Johannes L. Synthesis and properties of a mitochondrial peripheral benzodiazepine receptor conjugate. ChemMedChem 2008, 3:1687-1695.
67. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171:45-50.
68. Engedal N., Skotland T., Torgersen M.L., Sandvig K. Shiga toxin and its use in targeted cancer therapy and imaging. Microb. Biotechnol. 2011, 4:32-46.
69. Erwert R.D., Eiting K.T., Tupper J.C., Winn R.K., Harlan J.M., Bannerman D.D. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb. Pathog. 2003, 35:87-93.
70. Facchini L.M., Lingwood C.A. A verotoxin 1 B subunit-lambda CRO chimeric protein specifically binds both DNA and globotriaosylceramide (Gb(3)) to effect nuclear targeting of exogenous DNA in Gb(3) positive cells. Exp. Cell. Res. 2001, 269:117-129.
71. Fagerquist C.K., Sultan O. Top-down proteomic identification of furin-cleaved α-subunit of Shiga toxin 2 from Escherichia coli O157:H7 using MALDI-TOF-TOF-MS/MS. J. Biomed. Biotechnol. 2010, 2010:123460.
72. Falguières T., Mallard F., Baron C., Hanau D., Lingwood C., Goud B., Salamero J., Johannes L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell. 2001, 12:2453-2468.
73. Farkas-Himsley H., Hill R., Rosen B., Arab S., Lingwood C.A. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. U S A 1995, 92:6996-7000.
74. Flagler M.J., Mahajan S.S., Kulkarni A.A., Iyer S.S., Weiss A.A. Comparison of binding platforms yields insights into receptor binding differences between Shiga toxins 1 and 2. Biochemistry 2010, 49:1649-1657.
75. Foster G.H., Tesh V.L. Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha. J. Leukoc. Biol. 2002, 71:107-114.
76. Frank C., Werber D., Cramer J.P., Askar M., Faber M., an der Heiden M., Bernard H., Fruth A., Prager R., Spode A., Wadl M., Zoufaly A., Jordan S., Kemper M.J., Follin P., Müller L., King L.A., Rosner B., Buchholz U., Stark K., Krause G. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 2011, 365:1771-1780.
77. Fraser M.E., Chernaia M.M., Kozlov Y.V., James M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5å resolution. Nat. Struct. Biol. 1994, 1:59-64.
78. Fraser M.E., Fujinaga M., Cherney M.M., Melton-Celsa A.R., Twiddy E.M., O'Brien A.D., James M.N.G. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 2004, 279:27511-27517.
79. Fraser M.E., Cherney M.M., Marcato P., Mulvey G.L., Armstrong G.D., James M.N.G. Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2006, 62:627-630.
80. Fuchs E., Haas A.K., Spooner R.A., Yoshimura S., Lord J.M., Barr F.A. Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways. J. Cell. Biol. 2007, 177:1133-1143.
81. Fujii J., Matsui T., Heatherly D.P., Schlegel K.H., Lobo P.I., Yutsudo T., Ciraolo G.M., Morris R.E., Obrig T. Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect. Immun. 2003, 71:2724-2735.
82. Fujii J., Wood K., Matsuda F., Carneiro-Filho B.A., Schlegel K.H., Yutsudo T., Binnington-Boyd B., Lingwood C.A., Obata F., Kim K.S., Yoshida S., Obrig T. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect. Immun. 2008, 76:3679-3689.
83. Fuller C.A., Pellino C.A., Flagler M.J., Strasser J.E., Weiss A.A. Shiga toxin subtypes display dramatic differences in potency. Infect. Immun. 2011, 79:1329-1337.
84. Gallegos K.M., Conrady D.G., Karve S.S., Gunasekera T.S., Herr A.B., Weiss A.A. Shiga toxin binding to glycolipids and glycans. PLoS ONE 2012, 7:e30368.
85. Gamage S.D., Strasser J.E., Chalk C.L., Weiss A.A. Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect. Immun. 2003, 71:3107-3115.
86. Gamage S.D., Patton A.K., Strasser J.E., Chalk C.L., Weiss A.A. Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine. Infect. Immun. 2006, 74:1977-1983.
87. Garred O., van Deurs B., Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J. Biol. Chem. 1995, 270:10817-10821.
88. Garred O., Dubinina E., Holm P.K., Olsnes S., van Deurs B., Kozlov J.V., Sandvig K. Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp. Cell. Res. 1995, 218:39-49.
89. Garred O., Dubinina E., Polesskaya A., Olsnes S., Kozlov J., Sandvig K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J. Biol. Chem. 1997, 272:11414-11419.
90. Girod A., Storrie B., Simpson J.C., Johannes L., Goud B., Roberts L.M., Lord J.M., Nilsson T., Pepperkok R. Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat. Cell. Biol. 1999, 1:423-430.
91. Gokool S., Tattersall D., Seaman M.N.J. EHD1 interacts with retromer to stabilize SNX1 tubules and facilitate endosome-to-Golgi retrieval. Traffic 2007, 8:1873-1886.
92. Gyles C.L., De Grandis S.A., MacKenzie C., Brunton J.L. Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of Escherichia coli. Microb. Pathog. 1988, 5:419-426.
93. Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., Regnault A., Desaymard C., Amigorena S., Ricciardi-Castagnoli P., Goud B., Fridman W.H., Johannes L., Tartour E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 2000, 165:3301-3308.
94. Hakomori S., Zhang Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 1997, 4:97-104.
95. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
96. Hansen C.G., Bright N.A., Howard G., Nichols B.J. SDPR induces membrane curvature and functions in the formation of caveolae. Nat. Cell. Biol. 2009, 11:807-814.
97. Head S.C., Karmali M.A., Lingwood C.A. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J. Biol. Chem. 1991, 266:3617-3621.
98. Heath-Engel H.M., Lingwood C.A. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003, 6:129-141.
99. Hehnly H., Sheff D., Stamnes M. Shiga toxin facilitates its retrograde transport by modifying microtubule dynamics. Mol. Biol. Cell. 2006, 17:4379-4389.
100. Hehnly H., Longhini K.M., Chen J.-L., Stamnes M. Retrograde Shiga toxin trafficking is regulated by ARHGAP21 and Cdc42. Mol. Biol. Cell. 2009, 20:4303-4312.
101. Hoey D.E.E., Sharp L., Currie C., Lingwood C.A., Gally D.L., Smith D.G.E. Verotoxin 1 binding to intestinal crypt epithelial cells results in localization to lysosomes and abrogation of toxicity. Cell. Microbiol. 2003, 5:85-97.
102. Houghton F.J., Chew P.L., Lodeho S., Goud B., Gleeson P.A. The localization of the Golgin GCC185 is independent of Rab6A/A' and Arl1. Cell 2009, 138:787-794.
103. Hovde C.J., Calderwood S.B., Mekalanos J.J., Collier R.J. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc. Natl. Acad. Sci. U S A 1988, 85:2568-2572.
104. Howard J.G. Observations on the intoxication produced in mice and rabbits by the neurotoxin of Shigella shigae. Br. J. Exp. Pathol. 1955, 36:439-446.
105. Iordanov M.S., Pribnow D., Magun J.L., Dinh T.H., Pearson J.A., Chen S.L., Magun B.E. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol. Cell. Biol. 1997, 17:3373-3381.
106. Ishitoya S., Kurazono H., Nishiyama H., Nakamura E., Kamoto T., Habuchi T., Terai A., Ogawa O., Yamamoto S. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J. Urol. 2004, 171:1309-1313.
107. Itoh K., Tezuka T., Inoue K., Tada H., Suzuki T. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide. Tohoku J. Exp. Med. 2001, 195:237-243.
108. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G.T. Pathogenesis of Shigella diarrhea. XI. Isolation of a Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J. Exp. Med. 1986, 163:1391-1404.
109. Jacewicz M.S., Mobassaleh M., Gross S.K., Balasubramanian K.A., Daniel P.F., Raghavan S., McCluer R.H., Keusch G.T. Pathogenesis of Shigella diarrhea: XVII. A mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin. J. Infect. Dis. 1994, 169:538-546.
110. Jackson M.P., Neill R.J., O'Brien A.D., Holmes R.K., Newland J.W. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol. Lett. 1987, 44:109-114.
111. Jackson M.P., Newland J.W., Holmes R.K., O'Brien A.D. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb. Pathog. 1987, 2:147-153.
112. Jackson M.P., Wadolkowski E.A., Weinstein D.L., Holmes R.K., O'Brien A.D. Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis. J. Bacteriol. 1990, 172:653-658.
113. James C.E., Stanley K.N., Allison H.E., Flint H.J., Stewart C.S., Sharp R.J., Saunders J.R., McCarthy A.J. Lytic and lysogenic infection of diverse Escherichia coli and Shigella strains with a verocytotoxigenic bacteriophage. Appl. Environ. Microbiol. 2001, 67:4335-4337.
114. Jandhyala D.M., Ahluwalia A., Obrig T., Thorpe C.M. ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell. Microbiol. 2008, 10:1468-1477.
115. Janssen K.-P., Vignjevic D., Boisgard R., Falguières T., Bousquet G., Decaudin D., Dollé F., Louvard D., Tavitian B., Robine S., Johannes L. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res. 2006, 66:7230-7236.
116. Jemal C., Haddad J.E., Begum D., Jackson M.P. Analysis of Shiga toxin subunit association by using hybrid A polypeptides and site-specific mutagenesis. J. Bacteriol. 1995, 177:3128-3132.
117. Jing J., Junutula J.R., Wu C., Burden J., Matern H., Peden A.A., Prekeris R. FIP1/RCP binding to Golgin-97 regulates retrograde transport from recycling endosomes to the trans-Golgi network. Mol. Biol. Cell. 2010, 21:3041-3053.
118. Johannes L., Römer W. Shiga toxins - from cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8:105-116.
119. Johansen B.K., Wasteson Y., Granum P.E., Brynestad S. Mosaic structure of Shiga-toxin-2-encoding phages isolated from Escherichia coli O157:H7 indicates frequent gene exchange between lambdoid phage genomes. Microbiology 2001, 147:1929-1936.
120. Johansson D., Andersson C., Moharer J., Johansson A., Behnam-Motlagh P. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br. J. Cancer 2010, 102:383-391.
121. Johnson W.M., Lior H., Bezanson G.S. Cytotoxic Escherichia coli O157:H7 associated with haemorrhagic colitis in Canada. Lancet 1983, 1:76.
122. Jones N.L., Islur A., Haq R., Mascarenhas M., Karmali M.A., Perdue M.H., Zanke B.W., Sherman P.M. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278:G811-G819.
123. Kano F., Yamauchi S., Yoshida Y., Watanabe-Takahashi M., Nishikawa K., Nakamura N., Murata M. Yip1A regulates the COPI-independent retrograde transport from the Golgi complex to the ER. J. Cell. Sci. 2009, 122:2218-2227.
124. Karch H., Schmidt H., Janetzki-Mittmann C., Scheef J., Kröger M. Shiga toxins even when different are encoded at identical positions in the genomes of related temperate bacteriophages. Mol. Gen. Genet. 1999, 262:600-607.
125. Karch H., Tarr P.I., Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295:405-418.
126. Karmali M.A., Steele B.T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983, 1:619-620.
127. Katagiri Y.U., Mori T., Nakajima H., Katagiri C., Taguchi T., Takeda T., Kiyokawa N., Fujimoto J. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J. Biol. Chem. 1999, 274:35278-35282.
128. Keusch G.T., Grady G.F., Mata L.J., McIver J. The pathogenesis of Shigella diarrhea. I. Enterotoxin production by Shigella dysenteriae I. J. Clin. Invest. 1972, 51:1212-1218.
129. Keusch G.T., Grady G.F., Takeuchi A., Sprinz H. The pathogenesis of Shigella diarrhea. II. Enterotoxin-induced acute enteritis in the rabbit ileum. J. Infect. Dis. 1972, 126:92-95.
130. Keusch G.T., Donohue-Rolfe A., Jacewicz M. Shigella toxin(s): description and role in diarrhea and dysentery. Pharmacol. Ther. 1982, 15:403-438.
131. Khan F., Proulx F., Lingwood C.A. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. Kidney Int. 2009, 75:1209-1216.
132. Kiarash A., Boyd B., Lingwood C.A. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 1994, 269:11138-11146.
133. Kimmitt P.T., Harwood C.R., Barer M.R. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerging Infect. Dis. 2000, 6:458-465.
134. Kitov P.I., Sadowska J.M., Mulvey G., Armstrong G.D., Ling H., Pannu N.S., Read R.J., Bundle D.R. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000, 403:669-672.
135. Kitov P.I., Mulvey G.L., Griener T.P., Lipinski T., Solomon D., Paszkiewicz E., Jacobson J.M., Sadowska J.M., Suzuki M., Yamamura K.-I., Armstrong G.D., Bundle D.R. In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins. Proc. Natl. Acad. Sci. U S A 2008, 105:16837-16842.
136. Kitova E.N., Daneshfar R., Marcato P., Mulvey G.L., Armstrong G., Klassen J.S. Stability of the homopentameric B subunits of Shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry. J. Am. Soc. Mass. Spectrom. 2005, 16:1957-1968.
137. Kitova E.N., Kitov P.I., Paszkiewicz E., Kim J., Mulvey G.L., Armstrong G.D., Bundle D.R., Klassen J.S. Affinities of Shiga toxins 1 and 2 for univalent and oligovalent Pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. Glycobiology 2007, 17:1127-1137.
138. Kitova E.N., Mulvey G.L., Dingle T., Sinelnikov I., Wee S., Griener T.P., Armstrong G.D., Klassen J.S. Assembly and stability of the Shiga toxins investigated by electrospray ionization mass spectrometry. Biochemistry 2009, 48:5365-5374.
139. Kiyokawa N., Mori T., Taguchi T., Saito M., Mimori K., Suzuki T., Sekino T., Sato N., Nakajima H., Katagiri Y.U., Takeda T., Fujimoto J. Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt's lymphoma cells. J. Cell. Biochem. 2001, 81:128-142.
140. Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect. Immun. 1977, 18:775-779.
141. Konowalchuk J., Dickie N., Stavric S., Speirs J.I. Properties of an Escherichia coli cytotoxin. Infect. Immun. 1978, 20:575-577.
142. Kovbasnjuk O., Edidin M., Donowitz M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J. Cell. Sci. 2001, 114:4025-4031.
143. Kovbasnjuk O., Mourtazina R., Baibakov B., Wang T., Elowsky C., Choti M.A., Kane A., Donowitz M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. U S A 2005, 102:19087-19092.
144. Kurmanova A., Llorente A., Polesskaya A., Garred O., Olsnes S., Kozlov J., Sandvig K. Structural requirements for furin-induced cleavage and activation of Shiga toxin. Biochem. Biophys. Res. Commun. 2007, 357:144-149.
145. LaCasse E.C., Saleh M.T., Patterson B., Minden M.D., Gariépy J. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 1996, 88:1561-1567.
146. LaCasse E.C., Bray M.R., Patterson B., Lim W.M., Perampalam S., Radvanyi L.G., Keating A., Stewart A.K., Buckstein R., Sandhu J.S., Miller N., Banerjee D., Singh D., Belch A.R., Pilarski L.M., Gariépy J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999, 94:2901-2910.
147. LaPointe P., Wei X., Gariépy J. A role for the protease-sensitive loop region of Shiga-like toxin 1 in the retrotranslocation of its A1 domain from the endoplasmic reticulum lumen. J. Biol. Chem. 2005, 280:23310-23318.
148. Laufman O., Hong W., Lev S. The COG complex interacts directly with Syntaxin 6 and positively regulates endosome-to-TGN retrograde transport. J. Cell. Biol. 2011, 194:459-472.
149. Lauvrak S.U., Torgersen M.L., Sandvig K. Efficient endosome-to-Golgi transport of Shiga toxin is dependent on dynamin and clathrin. J. Cell. Sci. 2004, 117:2321-2331.
150. Lauvrak S.U., Wälchli S., Iversen T.-G., Slagsvold H.H., Torgersen M.L., Spilsberg B., Sandvig K. Shiga toxin regulates its entry in a Syk-dependent manner. Mol. Biol. Cell. 2006, 17:1096-1109.
151. Lavie Y., Cao H., Bursten S.L., Giuliano A.E., Cabot M.C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 1996, 271:19530-19536.
152. Lea N., Lord J.M., Roberts L.M. Proteolytic cleavage of the A subunit is essential for maximal cytotoxicity of Escherichia coli O157:H7 Shiga-like toxin-1. Microbiology 1999, 145(Pt 5):999-1004.
153. Lee R.S., Tartour E., van der Bruggen P., Vantomme V., Joyeux I., Goud B., Fridman W.H., Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 1998, 28:2726-2737.
154. Lee S.-Y., Lee M.-S., Cherla R.P., Tesh V.L. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell. Microbiol. 2008, 10:770-780.
155. Lentz E.K., Leyva-Illades D., Lee M.-S., Cherla R.P., Tesh V.L. Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2. Infect. Immun. 2011, 79:3527-3540.
156. Leung P.H.M., Peiris J.S.M., Ng W.W.S., Robins-Browne R.M., Bettelheim K.A., Yam W.C. A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli. Appl. Environ. Microbiol. 2003, 69:7549-7553.
157. Lindberg A.A., Brown J.E., Strömberg N., Westling-Ryd M., Schultz J.E., Karlsson K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 1987, 262:1779-1785.
158. Lindgren S.W., Samuel J.E., Schmitt C.K., O'Brien A.D. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect. Immun. 1994, 62:623-631.
159. Ling H., Boodhoo A., Hazes B., Cummings M.D., Armstrong G.D., Brunton J.L., Read R.J. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 1998, 37:1777-1788.
160. Ling H., Pannu N.S., Boodhoo A., Armstrong G.D., Clark C.G., Brunton J.L., Read R.J. A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity. Structure 2000, 8:253-264.
161. Lingwood C.A. Verotoxin-binding in human renal sections. Nephron 1994, 66:21-28.
162. Lingwood C.A., Law H., Richardson S., Petric M., Brunton J.L., De Grandis S., Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 1987, 262:8834-8839.
163. Lingwood C.A., Binnington B., Manis A., Branch D.R. Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect. FEBS Lett. 2010, 584:1879-1886.
164. Lingwood C.A., Manis A., Mahfoud R., Khan F., Binnington B., Mylvaganam M. New aspects of the regulation of glycosphingolipid receptor function. Chem. Phys. Lipids 2010, 163:27-35.
165. Lingwood D., Binnington B., Róg T., Vattulainen I., Grzybek M., Coskun U., Lingwood C.A., Simons K. Cholesterol modulates glycolipid conformation and receptor activity. Nat. Chem. Biol. 2011, 7:260-262.
166. Lu L., Tai G., Hong W. Autoantigen Golgin-97, an effector of Arl1 GTPase, participates in traffic from the endosome to the trans-Golgi network. Mol. Biol. Cell. 2004, 15:4426-4443.
167. Lucci A., Cho W.I., Han T.Y., Giuliano A.E., Morton D.L., Cabot M.C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. 1998, 18:475-480.
168. Luna A., Matas O.B., Martínez-Menárguez J.A., Mato E., Durán J.M., Ballesta J., Way M., Egea G. Regulation of protein transport from the Golgi complex to the endoplasmic reticulum by CDC42 and N-WASP. Mol. Biol. Cell. 2002, 13:866-879.
169. Maak M., Nitsche U., Keller L., Wolf P., Sarr M., Thiebaud M., Rosenberg R., Langer R., Kleeff J., Friess H., Johannes L., Janssen K.-P. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Mol. Cancer Ther. 2011, 10:1918-1928.
170. Magnus T., Röther J., Simova O., Meier-Cillien M., Repenthin J., Möller F., Gbadamosi J., Panzer U., Wengenroth M., Hagel C., Kluge S., Stahl R.K., Wegscheider K., Urban P., Eckert B., Glatzel M., Fiehler J., Gerloff C. The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 2012, 10.1093/brain/aws090.
171. Mahfoud R., Manis A., Lingwood C.A. Fatty acid-dependent globotriaosyl ceramide receptor function in detergent resistant model membranes. J. Lipid Res. 2009, 50:1744-1755.
172. Mahfoud R., Manis A., Binnington B., Ackerley C., Lingwood C.A. A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins. J. Biol. Chem. 2010, 285:36049-36059.
173. Mallard F., Antony C., Tenza D., Salamero J., Goud B., Johannes L. Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of Shiga toxin B-fragment transport. J. Cell. Biol. 1998, 143:973-990.
174. Mallard F., Tang B.L., Galli T., Tenza D., Saint-Pol A., Yue X., Antony C., Hong W., Goud B., Johannes L. Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6 isoform. J. Cell. Biol. 2002, 156:653-664.
175. Mangeney M., Lingwood C.A., Taga S., Caillou B., Tursz T., Wiels J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993, 53:5314-5319.
176. McDonough M.A., Butterton J.R. Spontaneous tandem amplification and deletion of the Shiga toxin operon in Shigella dysenteriae 1. Mol. Microbiol. 1999, 34:1058-1069.
177. Melton-Celsa A., Mohawk K., Teel L., O'Brien A. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr. Top. Microbiol. Immunol. 2012, 357:67-103.
178. Merrill A.H. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 2011, 111:6387-6422.
179. Miserey-Lenkei S., Chalancon G., Bardin S., Formstecher E., Goud B., Echard A. Rab and actomyosin-dependent fission of transport vesicles at the Golgi complex. Nat. Cell. Biol. 2010, 12:645-654.
180. Miura Y., Sasao Y., Dohi H., Nishida Y., Kobayashi K. Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with Shiga toxins. Anal. Biochem. 2002, 310:27-35.
181. Monier S., Jollivet F., Janoueix-Lerosey I., Johannes L., Goud B. Characterization of novel Rab6-interacting proteins involved in endosome-to-TGN transport. Traffic 2002, 3:289-297.
182. Moreau D., Kumar P., Wang S.C., Chaumet A., Chew S.Y., Chevalley H., Bard F. Genome-wide RNAi screens identify genes required for Ricin and PE intoxications. Dev. Cell. 2011, 21:231-244.
183. Mori T., Kiyokawa N., Katagiri Y.U., Taguchi T., Suzuki T., Sekino T., Sato N., Ohmi K., Nakajima H., Takeda T., Fujimoto J. Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. Exp. Hematol. 2000, 28:1260-1268.
184. Morjani H., Aouali N., Belhoussine R., Veldman R.J., Levade T., Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Cancer 2001, 94:157-165.
185. Mukhopadhyay S., Linstedt A.D. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012, 335:332-335.
186. Mukhopadhyay S., Bachert C., Smith D.R., Linstedt A.D. Manganese-induced trafficking and turnover of the cis-Golgi glycoprotein GPP130. Mol. Biol. Cell. 2010, 21:1282-1292.
187. Mulvey G.L., Marcato P., Kitov P.I., Sadowska J., Bundle D.R., Armstrong G.D. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. 2003, 187:640-649.
188. Muniesa M., Lucena F., Jofre J. Comparative survival of free Shiga toxin 2-encoding phages and Escherichia coli strains outside the gut. Appl. Environ. Microbiol. 1999, 65:5615-5618.
189. Nakajima H., Kiyokawa N., Katagiri Y.U., Taguchi T., Suzuki T., Sekino T., Mimori K., Ebata T., Saito M., Nakao H., Takeda T., Fujimoto J. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J. Biol. Chem. 2001, 276:42915-42922.
190. Naslavsky N., McKenzie J., Altan-Bonnet N., Sheff D., Caplan S. EHD3 regulates early-endosome-to-Golgi transport and preserves Golgi morphology. J. Cell. Sci. 2009, 122:389-400.
191. Natarajan R., Linstedt A.D. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. Mol. Biol. Cell. 2004, 15:4798-4806.
192. Nathanson S., Kwon T., Elmaleh M., Charbit M., Launay E.A., Harambat J., Brun M., Ranchin B., Bandin F., Cloarec S., Bourdat-Michel G., Piètrement C., Champion G., Ulinski T., Deschênes G. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2010, 5:1218-1228.
193. Neely M.N., Friedman D.I. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of Shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol. Microbiol. 1998, 28:1255-1267.
194. Neisser M., Shiga K. Ueber freie Receptoren von Typhus- und Dysenteriebazillen und über das Dysenterietoxin. Dtsch. Med. Wochenschr 1903, 29:61-62.
195. Newland J.W., Strockbine N.A., Miller S.F., O'Brien A.D., Holmes R.K. Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli. Science 1985, 230:179-181.
196. Nichols B.J., Kenworthy A.K., Polishchuk R.S., Lodge R., Roberts T.H., Hirschberg K., Phair R.D., Lippincott-Schwartz J. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J. Cell. Biol. 2001, 153:529-541.
197. Nishikawa K., Matsuoka K., Kita E., Okabe N., Mizuguchi M., Hino K., Miyazawa S., Yamasaki C., Aoki J., Takashima S., Yamakawa Y., Nishijima M., Terunuma D., Kuzuhara H., Natori Y. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. U S A 2002, 99:7669-7674.
198. Nishikawa K., Matsuoka K., Watanabe M., Igai K., Hino K., Hatano K., Yamada A., Abe N., Terunuma D., Kuzuhara H., Natori Y. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J. Infect. Dis. 2005, 191:2097-2105.
199. Nishikawa K., Watanabe M., Kita E., Igai K., Omata K., Yaffe M.B., Natori Y. A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 2006, 20:2597-2599.
200. Nishimoto-Morita K., Shin H.-W., Mitsuhashi H., Kitamura M., Zhang Q., Johannes L., Nakayama K. Differential effects of depletion of ARL1 and ARFRP1 on membrane trafficking between the trans-Golgi network and endosomes. J. Biol. Chem. 2009, 284:10583-10592.
201. Noakes K.L., Teisserenc H.T., Lord J.M., Dunbar P.R., Cerundolo V., Roberts L.M. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett. 1999, 453:95-99.
202. Obata F., Tohyama K., Bonev A.D., Kolling G.L., Keepers T.R., Gross L.K., Nelson M.T., Sato S., Obrig T.G. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J. Infect. Dis. 2008, 198:1398-1406.
203. Ohmura M., Yamasaki S., Kurazono H., Kashiwagi K., Igarashi K., Takeda Y. Characterization of non-toxic mutant toxins of Vero toxin 1 that were constructed by replacing amino acids in the A subunit. Microb. Pathog. 1993, 15:169-176.
204. Okuda T., Tokuda N., Numata S., Ito M., Ohta M., Kawamura K., Wiels J., Urano T., Tajima O., Furukawa K., Furukawa K. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 2006, 281:10230-10235.
205. Olitsky P.K., Kligler I.J. Toxins and antitoxins of Bacillus dysenteriae Shiga. J. Exp. Med. 1920, 31:19-33.
206. Oloomi M., Bouzari S., Shariati E. In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: assessment of its immunogenicity and toxicity. Iran. Biomed. J. 2010, 14:136-141.
207. Olsnes S., Eiklid K. Isolation and characterization of Shigella shigae cytotoxin. J. Biol. Chem. 1980, 255:284-289.
208. Olsnes S., Reisbig R., Eiklid K. Subunit structure of Shigella cytotoxin. J. Biol. Chem. 1981, 256:8732-8738.
209. O'Brien A.D., LaVeck G.D., Griffin D.E., Thompson M.R. Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography. Infect. Immun. 1980, 30:170-179.
210. O'Brien A.D., LaVeck G.D., Thompson M.R., Formal S.B. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J. Infect. Dis. 1982, 146:763-769.
211. O'Brien A.O., Lively T.A., Chen M.E., Rothman S.W., Formal S.B. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet 1983, 1:702.
212. O'Brien A.D., Newland J.W., Miller S.F., Holmes R.K., Smith H.W., Formal S.B. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 1984, 226:694-696.
213. O'Brien A.D., Tesh V.L., Donohue-Rolfe A., Jackson M.P., Olsnes S., Sandvig K., Lindberg A.A., Keusch G.T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 1992, 180:65-94.
214. Palermo M.S., Exeni R.A., Fernández G.C. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev. Anti Infect. Ther. 2009, 7:697-707.
215. Paton A.W., Paton J.C. Enterobacter cloacae producing a Shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome. J. Clin. Microbiol. 1996, 34:463-465.
216. Pellizzari A., Pang H., Lingwood C.A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992, 31:1363-1370.
217. Perera L.P., Samuel J.E., Holmes R.K., O'Brien A.D. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity. J. Bacteriol. 1991, 173:1151-1160.
218. Pérez-Victoria F.J., Mardones G.A., Bonifacino J.S. Requirement of the human GARP complex for mannose 6-phosphate-receptor-dependent sorting of cathepsin D to lysosomes. Mol. Biol. Cell. 2008, 19:2350-2362.
219. Pernet-Gallay K., Antony C., Johannes L., Bornens M., Goud B., Rios R.M. The overexpression of GMAP-210 blocks anterograde and retrograde transport between the ER and the Golgi apparatus. Traffic 2002, 3:822-832.
220. Peter M.G., Lingwood C.A. Apparent cooperativity in multivalent verotoxin-globotriaosyl ceramide binding: kinetic and saturation binding studies with [(125)I]verotoxin. Biochim. Biophys. Acta 2000, 1501:116-124.
221. Petric M., Karmali M.A., Richardson S., Cheung R. Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 1987, 41:63-68.
222. Piérard D., Muyldermans G., Moriau L., Stevens D., Lauwers S. Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J. Clin. Microbiol. 1998, 36:3317-3322.
223. Popoff V., Mardones G.A., Tenza D., Rojas R., Lamaze C., Bonifacino J.S., Raposo G., Johannes L. The retromer complex and clathrin define an early endosomal retrograde exit site. J. Cell. Sci. 2007, 120:2022-2031.
224. Popoff V., Mardones G.A., Bai S.-K., Chambon V., Tenza D., Burgos P.V., Shi A., Benaroch P., Urbé S., Lamaze C., Grant B.D., Raposo G., Johannes L. Analysis of articulation between clathrin and retromer in retrograde sorting on early endosomes. Traffic 2009, 10:1868-1880.
225. Pust S., Dyve A.B., Torgersen M.L., van Deurs B., Sandvig K. Interplay between toxin transport and flotillin localization. PLoS ONE 2010, 5:e8844.
226. Raa H., Grimmer S., Schwudke D., Bergan J., Wälchli S., Skotland T., Shevchenko A., Sandvig K. Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. Traffic 2009, 10:868-882.
227. Reisbig R., Olsnes S., Eiklid K. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60S ribosomal subunit. J. Biol. Chem. 1981, 256:8739-8744.
228. Ren J., Utsunomiya I., Taguchi K., Ariga T., Tai T., Ihara Y., Miyatake T. Localization of verotoxin receptors in nervous system. Brain Res. 1999, 825:183-188.
229. Riley L.W., Remis R.S., Helgerson S.D., McGee H.B., Wells J.G., Davis B.R., Hebert R.J., Olcott E.S., Johnson L.M., Hargrett N.T., Blake P.A., Cohen M.L. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 1983, 308:681-685.
230. Rohde H., Qin J., Cui Y., Li D., Loman N.J., Hentschke M., Chen W., Pu F., Peng Y., Li J., Xi F., Li S., Li Y., Zhang Z., Yang X., Zhao M., Wang P., Guan Y., Cen Z., Zhao X., Christner M., Kobbe R., Loos S., Oh J., Yang L., Danchin A., Gao G.F., Song Y., Li Y., Yang H., Wang J., Xu J., Pallen M.J., Wang J., Aepfelbacher M., Yang R. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N. Engl. J. Med. 2011, 365:718-724.
231. Römer W., Berland L., Chambon V., Gaus K., Windschiegl B., Tenza D., Aly M.R.E., Fraisier V., Florent J.-C., Perrais D., Lamaze C., Raposo G., Steinem C., Sens P., Bassereau P., Johannes L. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007, 450:670-675.
232. Römer W., Pontani L.-L., Sorre B., Rentero C., Berland L., Chambon V., Lamaze C., Bassereau P., Sykes C., Gaus K., Johannes L. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. Cell 2010, 140:540-553.
233. Roudkenar M.H., Jafari A., Oloomi M., Bouzari S. Selective cytotoxicity of recombinant STXA1-GM-CSF protein in hematopoetic cancer cells. Cell. Biol. Toxicol. 2006, 22:213-219.
234. Rutjes N.W.P., Binnington B.A., Smith C.R., Maloney M.D., Lingwood C.A. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002, 62:832-845.
235. Ryd M., Alfredsson H., Blomberg L., Andersson A., Lindberg A.A. Purification of Shiga toxin by alpha-D-galactose-(1→4)-beta-D-galactose-(1→4)-beta-D-glucose-(1→) receptor ligand-based chromatography. FEBS Lett. 1989, 258:320-322.
236. Saint-Pol A., Yélamos B., Amessou M., Mills I.G., Dugast M., Tenza D., Schu P., Antony C., McMahon H.T., Lamaze C., Johannes L. Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev. Cell. 2004, 6:525-538.
237. Salhia B., Rutka J.T., Lingwood C., Nutikka A., Van Furth W.R. The treatment of malignant meningioma with verotoxin. Neoplasia 2002, 4:304-311.
238. Samuel J.E., Gordon V.M. Evidence that proteolytic separation of Shiga-like toxin type IIv A subunit into A1 and A2 subunits is not required for toxin activity. J. Biol. Chem. 1994, 269:4853-4859.
239. Sandvig K., Brown J.E. Ionic requirements for entry of Shiga toxin from Shigella dysenteriae 1 into cells. Infect. Immun. 1987, 55:298-303.
240. Sandvig K., Tønnessen T.I., Olsnes S. Ability of inhibitors of glycosylation and protein synthesis to sensitize cells to abrin, ricin, Shigella toxin, and Pseudomonas toxin. Cancer Res. 1986, 46:6418-6422.
241. Sandvig K., Olsnes S., Brown J.E., Petersen O.W., van Deurs B. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J. Cell. Biol. 1989, 108:1331-1343.
242. Sandvig K., Prydz K., Ryd M., van Deurs B. Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells. J. Cell. Biol. 1991, 113:553-562.
243. Sandvig K., Garred O., Prydz K., Kozlov J.V., Hansen S.H., van Deurs B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992, 358:510-512.
244. Sandvig K., Ryd M., Garred O., Schweda E., Holm P.K., van Deurs B. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J. Cell. Biol. 1994, 126:53-64.
245. Sandvig K., Garred O., van Helvoort A., van Meer G., van Deurs B. Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol. Biol. Cell. 1996, 7:1391-1404.
246. Sandvig K., Spilsberg B., Lauvrak S.U., Torgersen M.L., Iversen T.-G., van Deurs B. Pathways followed by protein toxins into cells. Int. J. Med. Microbiol. 2004, 293:483-490.
247. Sandvig K., Bergan J., Dyve A.-B., Skotland T., Torgersen M.L. Endocytosis and retrograde transport of Shiga toxin. Toxicon 2010, 56:1181-1185.
248. Sandvig K., Torgersen M.L., Engedal N., Skotland T., Iversen T.-G. Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Lett. 2010, 584:2626-2634.
249. Sandvig K., Pust S., Skotland T., van Deurs B. Clathrin-independent endocytosis: mechanisms and function. Curr. Opin. Cell. Biol. 2011, 23:1-8.
250. Saxena S.K., O'Brien A.D., Ackerman E.J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 1989, 264:596-601.
251. Schapiro F.B., Lingwood C., Furuya W., Grinstein S. pH-independent retrograde targeting of glycolipids to the Golgi complex. Am. J. Physiol. 1998, 274:C319-C332.
252. Scheutz, F., Beutin, L., Piérard, D., Karch, H., Tozzoli, R., Caprioli, A., O'Brien, A.D., Melton-Celsa, A.R., Teel, L.D., Strockbine, N., 2009. Nomenclature of Verocytotoxins: a Review, a Proposal, and a Protocol for Typing Vtx Genes. Presented at the 4th Annu. Workshop Commun. Ref. Lab. E. coli VTEC, ISS, Rome, Italy.
253. Schmidt H., Montag M., Bockemühl J., Heesemann J., Karch H. Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples. Infect. Immun. 1993, 61:534-543.
254. Schmidt H., Scheef J., Morabito S., Caprioli A., Wieler L.H., Karch H. A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl. Environ. Microbiol. 2000, 66:1205-1208.
255. Schmitt C.K., McKee M.L., O'Brien A.D. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. Infect. Immun. 1991, 59:1065-1073.
256. Scotland S.M., Day N., Rowe B. Production of a cytotoxin affecting Vero cells by strains of Escherichia coli belonging to traditional enteropathogenic serogroups. FEMS Microbiol. Lett. 1980, 7:15-17.
257. Scotland S.M., Willshaw G.A., Smith H.R., Rowe B. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 1987, 99:613-624.
258. Seidah N.G., Donohue-Rolfe A., Lazure C., Auclair F., Keusch G.T., Chrétien M. Complete amino acid sequence of Shigella toxin B-chain. A novel polypeptide containing 69 amino acids and one disulfide bridge. J. Biol. Chem. 1986, 261:13928-13931.
259. Shiga K. Ueber den Dysenterie-bacillus (Bacillus dysenteriae). Centralblatt für Bakteriologie, Parasitenkunde und Infektionskrankheiten, Erste Abteilung 1898, vol. 24. Medizinisch-hygienische Bakteriologie und tierische Parasitenkunde, pp. 913-918.
260. Shimizu T., Ohta Y., Noda M. Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect. Immun. 2009, 77:2813-2823.
261. Skånland S.S., Wälchli S., Sandvig K. beta-Arrestins attenuate p38 mediated endosome to Golgi transport. Cell. Microbiol. 2009, 11:796-807.
262. Skinner L.M., Jackson M.P. Investigation of ribosome binding by the Shiga toxin A1 subunit, using competition and site-directed mutagenesis. J. Bacteriol. 1997, 179:1368-1374.
263. Smith W.E., Kane A.V., Campbell S.T., Acheson D.W.K., Cochran B.H., Thorpe C.M. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun. 2003, 71:1497-1504.
264. Smith D.C., Sillence D.J., Falguières T., Jarvis R.M., Johannes L., Lord J.M., Platt F.M., Roberts L.M. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol. Biol. Cell. 2006, 17:1375-1387.
265. Soltyk A.M., MacKenzie C.R., Wolski V.M., Hirama T., Kitov P.I., Bundle D.R., Brunton J.L. A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. J. Biol. Chem. 2002, 277:5351-5359.
266. Starr T., Sun Y., Wilkins N., Storrie B. Rab33b and Rab6 are functionally overlapping regulators of Golgi homeostasis and trafficking. Traffic 2010, 11:626-636.
267. Stechmann B., Bai S.-K., Gobbo E., Lopez R., Merer G., Pinchard S., Panigai L., Tenza D., Raposo G., Beaumelle B., Sauvaire D., Gillet D., Johannes L., Barbier J. Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 2010, 141:231-242.
268. Stein P.E., Boodhoo A., Tyrrell G.J., Brunton J.L., Read R.J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992, 355:748-750.
269. Strauch E., Lurz R., Beutin L. Characterization of a Shiga toxin-encoding temperate bacteriophage of Shigella sonnei. Infect. Immun. 2001, 69:7588-7595.
270. Strockbine N.A., Marques L.R., Newland J.W., Smith H.W., Holmes R.K., O'Brien A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 1986, 53:135-140.
271. Strockbine N.A., Jackson M.P., Sung L.M., Holmes R.K., O'Brien A.D. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J. Bacteriol. 1988, 170:1116-1122.
272. Suhan M.L., Hovde C.J. Disruption of an internal membrane-spanning region in Shiga toxin 1 reduces cytotoxicity. Infect. Immun. 1998, 66:5252-5259.
273. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell. Biol. 2011, 13:184-190.
274. Taga S., Carlier K., Mishal Z., Capoulade C., Mangeney M., Lécluse Y., Coulaud D., Tétaud C., Pritchard L.L., Tursz T., Wiels J. Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood 1997, 90:2757-2767.
275. Tai G., Lu L., Wang T.L., Tang B.L., Goud B., Johannes L., Hong W. Participation of the syntaxin 5/Ykt6/GS28/GS15 SNARE complex in transport from the early/recycling endosome to the trans-Golgi network. Mol. Biol. Cell. 2004, 15:4011-4022.
276. Takenouchi H., Kiyokawa N., Taguchi T., Matsui J., Katagiri Y.U., Okita H., Okuda K., Fujimoto J. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J. Cell. Sci. 2004, 117:3911-3922.
277. Tam P.J., Lingwood C.A. Membrane cytosolic translocation of verotoxin A1 subunit in target cells. Microbiology 2007, 153:2700-2710.
278. Tam P., Mahfoud R., Nutikka A., Khine A.A., Binnington B., Paroutis P., Lingwood C. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J. Cell. Physiol. 2008, 216:750-763.
279. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365:1073-1086.
280. Tarragó-Trani M.T., Jiang S., Harich K.C., Storrie B. Shiga-like toxin subunit B (SLTB)-enhanced delivery of chlorin e6 (Ce6) improves cell killing. Photochem. Photobiol. 2006, 82:527-537.
281. Teel L.D., Melton-Celsa A.R., Schmitt C.K., O'Brien A.D. One of two copies of the gene for the activatable Shiga toxin type 2d in Escherichia coli O91:H21 strain B2F1 is associated with an inducible bacteriophage. Infect. Immun. 2002, 70:4282-4291.
282. Tesh V.L. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010, 5:431-453.
283. Tesh V.L. Activation of cell stress response pathways by Shiga toxins. Cell. Microbiol. 2012, 14:1-9.
284. Tesh V.L., Burris J.A., Owens J.W., Gordon V.M., Wadolkowski E.A., O'Brien A.D., Samuel J.E. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 1993, 61:3392-3402.
285. Thompson M.R., Steinberg M.S., Gemski P., Formal S.B., Doctor B.P. Inhibition of in vitro protein synthesis by Shigella dysenteriae 1 toxin. Biochem. Biophys. Res. Commun. 1976, 71:783-788.
286. Thorpe C.M., Hurley B.P., Lincicome L.L., Jacewicz M.S., Keusch G.T., Acheson D.W. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect. Immun. 1999, 67:5985-5993.
287. Torgersen M.L., Lauvrak S.U., Sandvig K. The A-subunit of surface-bound Shiga toxin stimulates clathrin-dependent uptake of the toxin. FEBS J. 2005, 272:4103-4113.
288. Torgersen M.L., Wälchli S., Grimmer S., Skånland S.S., Sandvig K. Protein kinase Cdelta is activated by Shiga toxin and regulates its transport. J. Biol. Chem. 2007, 282:16317-16328.
289. Torgersen M.L., Engedal N., Bergan J., Sandvig K. The intracellular journey of Shiga toxins. Open Toxinol. J. 2010, 3:3-12.
290. Torgersen M.L., Engedal N., Pedersen A.-M.G., Husebye H., Espevik T., Sandvig K. Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells. FEMS Immunol. Med. Microbiol. 2011, 61:63-75.
291. Tóth I., Schmidt H., Dow M., Malik A., Oswald E., Nagy B. Transduction of porcine enteropathogenic Escherichia coli with a derivative of a Shiga toxin 2-encoding bacteriophage in a porcine ligated ileal loop system. Appl. Environ. Microbiol. 2003, 69:7242-7247.
292. Trachtman H., Cnaan A., Christen E., Gibbs K., Zhao S., Acheson D.W.K., Weiss R., Kaskel F.J., Spitzer A., Hirschman G.H. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003, 290:1337-1344.
293. Trofa A.F., Ueno-Olsen H., Oiwa R., Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin. Infect. Dis. 1999, 29:1303-1306.
294. Tschape H., Prager R., Streckel W., Fruth A., Tietze E., Böhme G. Verotoxinogenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: green butter as the infection source. Epidemiol. Infect. 1995, 114:441-450.
295. Tyrrell G.J., Ramotar K., Toye B., Boyd B., Lingwood C.A., Brunton J.L. Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc. Natl. Acad. Sci. U S A 1992, 89:524-528.
296. Unkmeir A., Schmidt H. Structural analysis of phage-borne stx genes and their flanking sequences in Shiga toxin-producing Escherichia coli and Shigella dysenteriae type 1 strains. Infect. Immun. 2000, 68:4856-4864.
297. Utskarpen A., Slagsvold H.H., Dyve A.B., Skånland S.S., Sandvig K. SNX1 and SNX2 mediate retrograde transport of Shiga toxin. Biochem. Biophys. Res. Commun. 2007, 358:566-570.
298. Utskarpen A., Massol R., van Deurs B., Lauvrak S.U., Kirchhausen T., Sandvig K. Shiga toxin increases formation of clathrin-coated pits through Syk kinase. PLoS ONE 2010, 5:e10944.
299. Valderrama F., Durán J.M., Babià T., Barth H., Renau-Piqueras J., Egea G. Actin microfilaments facilitate the retrograde transport from the Golgi complex to the endoplasmic reticulum in mammalian cells. Traffic 2001, 2:717-726.
300. Van de Kar N.C., Monnens L.A., Van Hinsbergh V.W. Tumor necrosis factor and interleukin 1 induce expression of the glycolipid verotoxin receptor in human endothelial cells. Implications for the pathogenesis of the haemolytic uraemic syndrome. Behring Inst. Mitt 1993, 202-209.
301. Veldman R.J., Klappe K., Hinrichs J., Hummel I., van der Schaaf G., Sietsma H., Kok J.W. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J. 2002, 16:1111-1113.
302. Vicari G., Olitzki A.L., Olitzki Z. The action of the thermolabile toxin of Shigella dysenteriae on cells cultivated in vitro. Br. J. Exp. Pathol. 1960, 41:179-189.
303. Viel T., Dransart E., Nemati F., Henry E., Thézé B., Decaudin D., Lewandowski D., Boisgard R., Johannes L., Tavitian B. In vivo tumor targeting by the B-subunit of Shiga toxin. Mol. Imaging 2008, 7:239-247.
304. Vingert B., Adotevi O., Patin D., Jung S., Shrikant P., Freyburger L., Eppolito C., Sapoznikov A., Amessou M., Quintin-Colonna F., Fridman W.H., Johannes L., Tartour E. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol. 2006, 36:1124-1135.
305. Waddell T., Cohen A., Lingwood C.A. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc. Natl. Acad. Sci. U S A 1990, 87:7898-7901.
306. Wade W.G., Thom B.T., Evans N. Cytotoxic enteropathogenic Escherichia coli. Lancet 1979, 2:1235-1236.
307. Wagner P.L., Livny J., Neely M.N., Acheson D.W.K., Friedman D.I., Waldor M.K. Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli. Mol. Microbiol. 2002, 44:957-970.
308. Wälchli S., Skånland S.S., Gregers T.F., Lauvrak S.U., Torgersen M.L., Ying M., Kuroda S., Maturana A., Sandvig K. The Mitogen-activated protein kinase p38 links Shiga toxin-dependent signaling and trafficking. Mol. Biol. Cell. 2008, 19:95-104.
309. Wälchli S., Aasheim H.-C., Skånland S.S., Spilsberg B., Torgersen M.L., Rosendal K.R., Sandvig K. Characterization of clathrin and Syk interaction upon Shiga toxin binding. Cell. Signal. 2009, 21:1161-1168.
310. Watanabe M., Matsuoka K., Kita E., Igai K., Higashi N., Miyagawa A., Watanabe T., Yanoshita R., Samejima Y., Terunuma D., Natori Y., Nishikawa K. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J. Infect. Dis. 2004, 189:360-368.
311. Watanabe M., Igai K., Matsuoka K., Miyagawa A., Watanabe T., Yanoshita R., Samejima Y., Terunuma D., Natori Y., Nishikawa K. Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infect. Immun. 2006, 74:1984-1988.
312. Weinstein D.L., Jackson M.P., Samuel J.E., Holmes R.K., O'Brien A.D. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine. J. Bacteriol. 1988, 170:4223-4230.
313. Weinstein D.L., Jackson M.P., Perera L.P., Holmes R.K., O'Brien A.D. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity. Infect. Immun. 1989, 57:3743-3750.
314. Werber D., Fruth A., Buchholz U., Prager R., Kramer M.H., Ammon A., Tschäpe H. Strong association between Shiga toxin-producing Escherichia coli O157 and virulence genes stx2 and eae as possible explanation for predominance of serogroup O157 in patients with haemolytic uraemic syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22:726-730.
315. White J., Johannes L., Mallard F., Girod A., Grill S., Reinsch S., Keller P., Tzschaschel B., Echard A., Goud B., Stelzer E.H. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. J. Cell. Biol. 1999, 147:743-760.
316. Wilcke M., Johannes L., Galli T., Mayau V., Goud B., Salamero J. Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-Golgi network. J. Cell. Biol. 2000, 151:1207-1220.
317. Wilson M.W., Bettelheim K.A. Cytotoxic Escherichia coli serotypes. Lancet 1980, 1:201.
318. Windschiegl B., Orth A., Römer W., Berland L., Stechmann B., Bassereau P., Johannes L., Steinem C. Lipid reorganization induced by Shiga toxin clustering on planar membranes. PLoS ONE 2009, 4:e6238.
319. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 2000, 342:1930-1936.
320. Yahi N., Aulas A., Fantini J. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40). PLoS ONE 2010, 5:e9079.
321. Yamane J., Kubo A., Nakayama K., Yuba-Kubo A., Katsuno T., Tsukita S., Tsukita S. Functional involvement of TMF/ARA160 in Rab6-dependent retrograde membrane traffic. Exp. Cell. Res. 2007, 313:3472-3485.
322. Yamasaki S., Furutani M., Ito K., Igarashi K., Nishibuchi M., Takeda Y. Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. Microb. Pathog. 1991, 11:1-9.
323. Yoshimura S., Gerondopoulos A., Linford A., Rigden D.J., Barr F.A. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. J. Cell. Biol. 2010, 191:367-381.
324. Yoshino A., Setty S.R.G., Poynton C., Whiteman E.L., Saint-Pol A., Burd C.G., Johannes L., Holzbaur E.L., Koval M., McCaffery J.M., Marks M.S. tGolgin-1 (p230, golgin-245) modulates Shiga-toxin transport to the Golgi and Golgi motility towards the microtubule-organizing centre. J. Cell. Sci. 2005, 118:2279-2293.
325. Yu M., Haslam D.B. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect. Immun. 2005, 73:2524-2532.
326. Zhang X., McDaniel A.D., Wolf L.E., Keusch G.T., Waldor M.K., Acheson D.W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 2000, 181:664-670.
327. Zhang W., Bielaszewska M., Kuczius T., Karch H. Identification, characterization, and distribution of a Shiga toxin 1 gene variant (stx(1c)) in Escherichia coli strains isolated from humans. J. Clin. Microbiol. 2002, 40:1441-1446.
328. Zolov S.N., Lupashin V.V. Cog3p depletion blocks vesicle-mediated Golgi retrograde trafficking in HeLa cells. J. Cell. Biol. 2005, 168:747-759.